individuals who present one or more of the following characteristics will not be eligible to participate in this study: know or suspect that you are allergic to any of the components of azvudine tablets (inactive ingredients: microcrystalline cellulose, lactose hydrate, polyvinylpyrrolidone k30, croscarmellose sodium, magnesium stearate); individual presenting shortness of breath and sat o2 < 95%; or any other symptom requiring treatment through hospital admission; patients with liver disease (total bilirubin ≥2mg/dl, alt/tgp e ast/tgo ≥5 times above normal limit); pactients with a history of known liver disease (cirrhosis with childpugh classification b and c); patients with a history of renal insufficiency (glomerular filtration rate < 60ml/min/1,73m2); patients with history of congestive heart failure (nyha ¾ grade), untreated symptomatic arrhythmias ormyocardial infarction within 6 months; individuals with malabsorption syndrome, or other conditions affecting gastrointestinal absorption, and circumstances in which patients require intravenous nutrition, or cannot take medications orally or nasogastrically; total neutrophil count <750 cells/l;

individuals who present one or more of the following characteristics will not be eligible to participate in this study: know or suspect that you are allergic to any of the components of azvudine tablets (inactive ingredients: microcrystalline cellulose, lactose hydrate, polyvinylpyrrolidone k30, croscarmellose sodium, magnesium stearate); individual presenting shortness of breath and sat o2 < 95%; or any other symptom requiring treatment through hospital admission; patients with liver disease (total bilirubin ≥2mg/dl, alt/tgp e ast/tgo ≥5 times above normal limit); pactients with a history of known liver disease (cirrhosis with childpugh classification b and c); patients with a history of renal insufficiency (glomerular filtration rate < 60ml/min/1,73m2); patients with history of congestive heart failure (nyha ¾ grade), untreated symptomatic arrhythmias ormyocardial infarction within 6 months; individuals with malabsorption syndrome, or other conditions affecting gastrointestinal absorption, and circumstances in which patients require intravenous nutrition, or cannot take medications orally or nasogastrically; total neutrophil count <750 cells/l;

be aware or suspected of being allergic to any of the components of azvudine tablets (inactive ingredients: microcrystalline cellulose, hydrated lactose, polyvinylpyrrolidone k30, croscarmellose sodium, magnesium stearate); individual with shortness of breath and sat o2 < 95%; or any other symptom that requires treatment through hospitalization; patients with liver disease (total bilirubin ≥2mg/dl, alt/tgp, and ast/tgo ≥5 times the normal limit); patients with a history of known liver disease (chirrhosis, with childpugh classification b and c); patients with a history of renal failure (glomerular filtration rate </=60ml/min/1.73m²); patients with a history of congestive heart failure (grade 3/4 nyha), untreated symptomatic arrhythmias, or myocardial infarction for 6 months; individuals with malabsorption syndrome, or other conditions that affect gastrointestinal absorption, and circumstances in which patients require intravenous nutrition, or cannot take medications by mouth or nasogastric; total neutrophil count <750 cells/l; women who are pregnant or lactating, or of childbearing potential during the study period and within 6 months after termination of administration; individuals who have participated in another clinical trial and used an experimental drug in the past 12 weeks; patient actively being treated for hiv, hepatitis c, or hepatitis b; patients being treated with other antivirals (e.g., lopinavir/ritonavir, remdesivir, umifenovir/arbidol, favipiravir, interferon-α) or immunosuppressive drugs for other medical conditions; patients being treated with monoclonal antibodies (e.g., tocilizumab and sarilumab/kevzara); any clinically significant medical condition or medical history that, in the investigator's opinion, may discourage study participation, such as corrected qt interval >480 on the electrocardiogram, among other conditions.

be aware or suspected of being allergic to any of the components of azvudine tablets (inactive ingredients: microcrystalline cellulose, hydrated lactose, polyvinylpyrrolidone k30, croscarmellose sodium, magnesium stearate); individual with shortness of breath and sat o2 < 95%; or any other symptom that requires treatment through hospitalization; patients with liver disease (total bilirubin ≥2mg/dl, alt/tgp, and ast/tgo ≥5 times the normal limit); patients with a history of known liver disease (chirrhosis, with childpugh classification b and c); patients with a history of renal failure (glomerular filtration rate </=60ml/min/1.73m²); patients with a history of congestive heart failure (grade 3/4 nyha), untreated symptomatic arrhythmias, or myocardial infarction for 6 months; individuals with malabsorption syndrome, or other conditions that affect gastrointestinal absorption, and circumstances in which patients require intravenous nutrition, or cannot take medications by mouth or nasogastric; total neutrophil count <750 cells/l; women who are pregnant or lactating, or of childbearing potential during the study period and within 6 months after termination of administration; individuals who have participated in another clinical trial and used an experimental drug in the past 12 weeks; patient actively being treated for hiv, hepatitis c, or hepatitis b; patients being treated with other antivirals (e.g., lopinavir/ritonavir, remdesivir, umifenovir/arbidol, favipiravir, interferon-α) or immunosuppressive drugs for other medical conditions; patients being treated with monoclonal antibodies (e.g., tocilizumab and sarilumab/kevzara); any clinically significant medical condition or medical history that, in the investigator's opinion, may discourage study participation, such as corrected qt interval >480 on the electrocardiogram, among other conditions.

1. be aware or suspected of being allergic to any of the components of azvudine tablets (inactive ingredients: microcrystalline cellulose, hydrated lactose, polyvinylpyrrolidone k30, croscarmellose sodium, magnesium stearate); 2. individual with shortness of breath and sat o2 < 95%; or any other symptom that requires treatment through hospitalization; 3. patients with liver disease (total bilirubin ≥2mg/dl, alt/tgp, and ast/tgo ≥5 times the normal limit); 4. patients with a history of known liver disease (chirrhosis, with childpugh classification b and c); 5. patients with a history of renal failure (glomerular filtration rate </=60ml/min/1.73m²); 6. patients with a history of congestive heart failure (grade 3/4 nyha), untreated symptomatic arrhythmias, or myocardial infarction for 6 months; 7. individuals with malabsorption syndrome, or other conditions that affect gastrointestinal absorption, and circumstances in which patients require intravenous nutrition, or cannot take medications by mouth or nasogastric; 8. total neutrophil count <750 cells/l; 9. women who are pregnant or lactating, or of childbearing potential during the study period and within 6 months after termination of administration; 10. individuals who have participated in another clinical trial and used an experimental drug in the past 12 weeks; 11. patient actively being treated for hiv, hepatitis c, or hepatitis b; 12. patients being treated with other antivirals (e.g., lopinavir/ritonavir, remdesivir, umifenovir/arbidol, favipiravir, interferon-α) or immunosuppressive drugs for other medical conditions; 13. patients being treated with monoclonal antibodies (e.g., tocilizumab and sarilumab/kevzara); 14. any clinically significant medical condition or medical history that, in the investigator's opinion, may discourage study participation, such as corrected qt interval >480 on the electrocardiogram, among other conditions.

1. be aware or suspected of being allergic to any of the components of azvudine tablets (inactive ingredients: microcrystalline cellulose, hydrated lactose, polyvinylpyrrolidone k30, croscarmellose sodium, magnesium stearate); 2. individual with shortness of breath and sat o2 < 95%; or any other symptom that requires treatment through hospitalization; 3. patients with liver disease (total bilirubin ≥2mg/dl, alt/tgp, and ast/tgo ≥5 times the normal limit); 4. patients with a history of known liver disease (chirrhosis, with childpugh classification b and c); 5. patients with a history of renal failure (glomerular filtration rate </=60ml/min/1.73m²); 6. patients with a history of congestive heart failure (grade 3/4 nyha), untreated symptomatic arrhythmias, or myocardial infarction for 6 months; 7. individuals with malabsorption syndrome, or other conditions that affect gastrointestinal absorption, and circumstances in which patients require intravenous nutrition, or cannot take medications by mouth or nasogastric; 8. total neutrophil count <750 cells/l; 9. women who are pregnant or lactating, or of childbearing potential during the study period and within 6 months after termination of administration; 10. individuals who have participated in another clinical trial and used an experimental drug in the past 12 weeks; 11. patient actively being treated for hiv, hepatitis c, or hepatitis b; 12. patients being treated with other antivirals (e.g., lopinavir/ritonavir, remdesivir, umifenovir/arbidol, favipiravir, interferon-α) or immunosuppressive drugs for other medical conditions; 13. patients being treated with monoclonal antibodies (e.g., tocilizumab and sarilumab/kevzara); 14. any clinically significant medical condition or medical history that, in the investigator's opinion, may discourage study participation, such as corrected qt interval >480 on the electrocardiogram, among other conditions.